SLOW-RELEASE FORMULATION FOR RECOMBINANT BOVINE INTERFERON ALPHA(I)-1

Citation
Hpa. Hughes et al., SLOW-RELEASE FORMULATION FOR RECOMBINANT BOVINE INTERFERON ALPHA(I)-1, Antiviral research, 23(1), 1994, pp. 33-44
Citations number
20
Categorie Soggetti
Virology
Journal title
ISSN journal
01663542
Volume
23
Issue
1
Year of publication
1994
Pages
33 - 44
Database
ISI
SICI code
0166-3542(1994)23:1<33:SFFRBI>2.0.ZU;2-3
Abstract
Recombinant bovine interferon-alpha(I)1 (rBoIFN-alpha) has known antiv iral and immunomodulatory effects which have been exploited to reduce clinical disease in a number of clinical situations including bovine r espiratory diseases. A slow release rBoIFN-alpha formulation may be of value to reduce bovine respiratory disease under field conditions by extending the period of protection, and hence improving the prophylact ic benefits of rBoIFN-alpha. In this report, we describe a formulation of rBoIFN-alpha in sesame oil containing calcium stearate which can s uccessfully sustain the release of rBoIFN-alpha over an 8-day period. Recombinant bovine IFN-alpha could be measured in serum for 8 days fol lowing treatment with an initial burst of release 6 h after injection. After a single subcutaneous depot injection of 50 mg and 100 mg of rB oIFN-alpha, initial serum levels reached 12-15 ng/ml and 25 ng/ml resp ectively. Correlating with this burst of release, there was a decrease in the number of circulating CD4(-)CD8(-)gamma delta(+) T lymphocytes , and a slight neutropenia. No alterations in other cell phenotypes te sted (CD4, CD8, CD2, CD6, B cells, monocytes or MHC class II) were obs erved, nor were there changes in lymphokine activated killer (LAK), na tural killer (NK) cell activity, or oxygen radical formation (assessed by reduction of nitroblue tetrazolium). However, despite the rapid an d short-lived burst of rBoIFN-alpha, levels of 2-5 oligoadenylate (2-5 A) synthetase remained elevated for 8 days. The sustained increase of 2-5 A synthetase was not due to the high initial dose released during the burst 6-12 h after injection, since injection of a bioavailable e quivalent dose of interferon induced a significant rise in 2-5 A synth etase activity for 4 days only. As 2-5 A synthetase is known to be a c orrelate of antiviral activity, we propose that this formulation of rB oIFN-alpha may be one approach to increase the window of protection, l eading to more effective prevention of bovine respiratory disease.